Seeking to raise profits, the board of Mylan NV two years ago authorized an aggressive bonus program for its top executives if they could meet certain targets. Last year, when they beat those targets, the stock soared – briefly – and chief executive officer Heather Bresch saw her pay rise to $18.9 million, double what she got in 2013.
But one reason profits rose was that the pharmaceutical company doubled the price of its popular EpiPen, used to treat allergic reactions. When consumers started complaining, the stock fell back to earth and the company has scrambled to meet those concerns while scrutiny from Congress ratchets up.